What is the address of Dr. Tom Zwaenepoel, Reumatologie?

The registered office of Dr. Tom Zwaenepoel, Reumatologie is located at Mortelveld 9A, 9320 Aalst.

Is Dr. Tom Zwaenepoel, Reumatologie still active?

Yes. According to the CBE (30 September 2026) Dr. Tom Zwaenepoel, Reumatologie is active, legal situation “Normale toestand”, started on 31 January 2018.

Is Dr. Tom Zwaenepoel, Reumatologie registered on Peppol?

Yes, Dr. Tom Zwaenepoel, Reumatologie is registered on the Peppol network with ID 0208:0689639910.

What is the enterprise number of Dr. Tom Zwaenepoel, Reumatologie?

The enterprise number of Dr. Tom Zwaenepoel, Reumatologie is BE0689639910.

When was Dr. Tom Zwaenepoel, Reumatologie founded?

Dr. Tom Zwaenepoel, Reumatologie was founded on 31 January 2018.

Who are the directors of Dr. Tom Zwaenepoel, Reumatologie?

According to the 2025 annual accounts, the directors of Dr. Tom Zwaenepoel, Reumatologie are: Tom Zwaenepoel.

Is Dr. Tom Zwaenepoel, Reumatologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 31 January 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Tom Zwaenepoel, Reumatologie make in 2025?

Dr. Tom Zwaenepoel, Reumatologie posted a profit after taxes of € 53,940 in financial year 2025.

What is the revenue of Dr. Tom Zwaenepoel, Reumatologie?

As a small company, Dr. Tom Zwaenepoel, Reumatologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 111,890.

Dr. Tom Zwaenepoel, Reumatologie (Private Limited)

Dossier Dr. Tom Zwaenepoel, Reumatologie, printed on 30 September 2026 from databakkes.be/en/0689639910/dr-tom-zwaenepoel-reumatologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Tom Zwaenepoel, Reumatologie from Aalst, company number BE0689639910, closed financial year 2025 with a result of € 53,940 after tax. For that financial year Dr. Tom Zwaenepoel, Reumatologie recorded a gross margin of € 111,890 and equity of € 332,533. Compared with financial year 2024, the result moved from € 101,387 to € 53,940. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Growing

€ 332,533

▲ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 53,940

▼ 47% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 24,426

▼ 16% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1,666 paid out

3 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 3,573

▲ 14% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 507,061

▼ 6% vs 2024

€ 59,274 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 37,503

▲ € 37,235 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 11,571

▼ 69% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 126,637 Gross margin 2022: € 126,637 First fiscal year in the series	€ 133,595 Gross margin 2023: € 133,595 ▲ 5% vs 2022 (€ 126,637) Favourable step	€ 201,422 Gross margin 2024: € 201,422 ▲ 51% vs 2023 (€ 133,595) Favourable step	€ 111,890 Gross margin 2025: € 111,890 ▼ 44% vs 2024 (€ 201,422) Unfavourable step	▼ 44%
Profit after taxes	€ 35,071 Profit after taxes 2022: € 35,071 First fiscal year in the series	€ 53,119 Profit after taxes 2023: € 53,119 ▲ 51% vs 2022 (€ 35,071) Favourable step	€ 101,387 Profit after taxes 2024: € 101,387 ▲ 91% vs 2023 (€ 53,119) Favourable step	€ 53,940 Profit after taxes 2025: € 53,940 ▼ 47% vs 2024 (€ 101,387) Unfavourable step	▼ 47%
Equity	€ 129,019 Equity 2022: € 129,019 First fiscal year in the series	€ 180,538 Equity 2023: € 180,538 ▲ 40% vs 2022 (€ 129,019) Favourable step	€ 280,258 Equity 2024: € 280,258 ▲ 55% vs 2023 (€ 180,538) Favourable step	€ 332,533 Equity 2025: € 332,533 ▲ 19% vs 2024 (€ 280,258) Favourable step	▲ 19%
Total debts	€ 670,339 Total debts 2022: € 670,339 First fiscal year in the series	€ 644,556 Total debts 2023: € 644,556 ▼ 4% vs 2022 (€ 670,339) Favourable step	€ 578,514 Total debts 2024: € 578,514 ▼ 10% vs 2023 (€ 644,556) Favourable step	€ 557,801 Total debts 2025: € 557,801 ▼ 4% vs 2024 (€ 578,514) Favourable step	▼ 4%
Cash	€ 34,024 Cash 2022: € 34,024 First fiscal year in the series	€ 8,491 Cash 2023: € 8,491 ▼ 75% vs 2022 (€ 34,024) Unfavourable step	€ 29,228 Cash 2024: € 29,228 ▲ 244% vs 2023 (€ 8,491) Favourable step	€ 24,426 Cash 2025: € 24,426 ▼ 16% vs 2024 (€ 29,228) Unfavourable step	▼ 16%
Land & buildings	€ 722,296 Land & buildings 2022: € 722,296 First fiscal year in the series	€ 701,613 Land & buildings 2023: € 701,613 ▼ 3% vs 2022 (€ 722,296) Unchanged	€ 680,931 Land & buildings 2024: € 680,931 ▼ 3% vs 2023 (€ 701,613) Unchanged	€ 667,477 Land & buildings 2025: € 667,477 ▼ 2% vs 2024 (€ 680,931) Unchanged	▼ 2%
Retained profit	€ 116,619 Retained profit 2022: € 116,619 First fiscal year in the series	€ 168,138 Retained profit 2023: € 168,138 ▲ 44% vs 2022 (€ 116,619) Favourable step	€ 267,858 Retained profit 2024: € 267,858 ▲ 59% vs 2023 (€ 168,138) Favourable step	€ 320,133 Retained profit 2025: € 320,133 ▲ 20% vs 2024 (€ 267,858) Favourable step	▲ 20%
Dividend	€ 1,600 Dividend 2022: € 1,600 First fiscal year in the series	€ 1,600 Dividend 2023: € 1,600 Unchanged (€ 1,600) Unchanged	€ 1,666 Dividend 2024: € 1,666 ▲ 4% vs 2023 (€ 1,600) Unchanged	€ 1,666 Dividend 2025: € 1,666 Unchanged (€ 1,666) Unchanged
Bank debt	€ 640,368 Bank debt 2022: € 640,368 First fiscal year in the series	€ 608,903 Bank debt 2023: € 608,903 ▼ 5% vs 2022 (€ 640,368) Favourable step	€ 540,052 Bank debt 2024: € 540,052 ▼ 11% vs 2023 (€ 608,903) Favourable step	€ 507,061 Bank debt 2025: € 507,061 ▼ 6% vs 2024 (€ 540,052) Favourable step	▼ 6%
Balance sheet total	€ 799,358 Balance sheet total 2022: € 799,358 First fiscal year in the series	€ 825,094 Balance sheet total 2023: € 825,094 ▲ 3% vs 2022 (€ 799,358) Unchanged	€ 858,772 Balance sheet total 2024: € 858,772 ▲ 4% vs 2023 (€ 825,094) Unchanged	€ 890,333 Balance sheet total 2025: € 890,333 ▲ 4% vs 2024 (€ 858,772) Unchanged	▲ 4%

Key figures of Dr. Tom Zwaenepoel, Reumatologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Tom Zwaenepoel, Reumatologie?

What happened at Dr. Tom Zwaenepoel, Reumatologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 53,940 (▼ 47% vs 2024). Source: NBB ↗
Jan 31, 2018 New establishment in Aalst. KBO
Jan 31, 2018 Start of the company according to the CBE. KBO

In short

From € 35,071 profit in 2022 to € 53,940 profit in 2025.

Paid € 99,822 in corporate taxes since 2022.

Best year ever: 2024, with € 101,387 profit.

Paid out € 6,532 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Tom Zwaenepoel, Reumatologie? We notify you, reason included.

Follow Dr. Tom Zwaenepoel, Reumatologie

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Tom Zwaenepoel

Dr. Tom Zwaenepoel, Reumatologie

Behind Dr. Tom Zwaenepoel, Reumatologie is Tom Zwaenepoel.

See the full network in the app

Directors

According to the 2025 annual accounts

Tom Zwaenepoel

Manager

Establishments

Establishment units

Physical locations of this company

Registered office

Mortelveld 9A

9320 Aalst

2.272.784.036

Mortelveld 9 box A

9320 Aalst

Active since 31 January 2018

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0689.639.910
VAT number: BE 0689.639.910
Registered office: Mortelveld 9A, 9320 Aalst
Names & denominations: Dr. Tom Zwaenepoel, Reumatologie
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 31 January 2018
Peppol: Active · Active since 31 Oct 2023
Contact: [email protected]

View on CBE Public ↗ Annual accounts (NBB) ↗